- Treatment of complicated skin and skin structure infections caused by susceptible organisms
(includes gram positive, gram-negative and anaerobes) - Treatment of complicated intra-abdominal infections
VIAL SIZE | 0.9% NaCl or D5W REQUIRED | FINAL CONCENTRATION |
50 mg | 5.3 mL | 10 mg/mL |
- Gently swirl to dissolve - immediately withdraw dose from vial and further dilute
- Diluted solution stable 6 hours at room temperature or 24 hours in fridge
- Reconstituted solution should be yellow-orange in colour; if not,discard
-Solutions Compatible: D5W, 0.9% NaCl, ringer's lactate
-Additives/Above Cassette Compatible: no information
-Y-site Compatible: amikacin, dobutamine, dopamine, gentamicin, lidocaine, morphine, norepinephrine, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, tobramycin
-Incompatible: amphotericin B, chlorpromazine, methylprednisolone, voriconazole
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
SC | NO |
IM | NO |
IV Direct | NO |
IV Intermittent Infusion | YES Usual dilution: in 100 mL minibag of NS Infusion time: over 30 - 60 minutes |
IV Continuous Infusion | NO |
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
- safety & efficacy not established in children
Adolescent / Adult:
- 100 mg IV initial dose, then 50 mg IV Q12H for 5 to 14 days
- No dosage adjustment required for renal impairment or after hemodialysis
- No dosage adjustment required for mild to moderate hepatiac impairment
- For severe hepatic impairment: 100 mg IV initial dose then 25 mg IV Q12H
- Most common: nausea, vomiting, diarrhea
- Local reactions at the IV infusion site: edema, pain
- Hypersensitivity reactions
- Monitor INR when used concomitantly with warfarin - decreased clearance of warfarin
- Structurally similar to tetracycline- therefore, not recommended for use in children<8 or in pregnancy. Permanent discoloration of the teeth may occur if used during tooth development.